Guard therapeutics

The Company conducts development and commercialization of treatment and diagnostics based on the alphamicroglobulin A1M protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin guard therapeutics a tissue repairer.

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. The program began with the company's CEO, Tobias Agervald, providing a summary of the strategic considerations and positive feedback from the FDA that form the basis for the next development stages of RMC, including a planned Phase 2b study in open-heart surgery. Furthermore, the discussion also covered the way forward and the strategy for an upcoming pivotal Phase 3 study. Professor David Goldsmith, adjunct professor at King's College in London and a globally recognized Key Opinion Leader in nephrology, delivered a comprehensive presentation on irreversible loss of kidney function following open-heart surgery, highlighting the lack of specific treatment options despite the significant medical need. Professor Goldsmith also discussed the main findings of the AKITA study, which included positive and clinically relevant long-term effects on kidney function after treatment with RMC

Guard therapeutics

See the webcast. Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. Learn more about the clinical development of RMC RMC, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue. Acute kidney injury is a large market. Guard Therapeutics announced that the U. Food and Drug Administration FDA granted RMC ROSgard Fast Track designation for reducing the risk of an irreversible loss of kidney function, initiation of kidney replacement therapy or death following open-chest cardiac surgery in patients who are at increased risk for acute kidney injury. Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC ROSgard in kidney transplantation. The company has thus achieved an important milestone by expanding the clinical development program to a second indication where RMC has the potential to protect against acute kidney injuries. Full study results are expected to be available in the first half of Financial calender Financial reports Share information Corporate governance General meetings. Press releases Event calender Analyses and presentations In media Subscribe. Latest Press Releases.

Guard Therapeutics Intrntnl AB publ.

.

In line with previous communication patient recruitment was prematurely stopped, and as expected the primary short-term endpoint, incidence of acute kidney injury AKI within 72 hours after surgery, was not reached. Importantly though, pre-defined secondary endpoints demonstrated the intended long-term benefit of RMC with improved kidney function compared to placebo. These results clearly support advancement in the clinical development program and highlight the potential of RMC as a novel short-term treatment for kidney protection. With these results we are back on track, strengthened in our confidence to establish a new and unique treatment for the prevention of kidney injuries in heart surgery and proceed with the clinical development of RMC as planned. The consistency between improved kidney function and MAKE reduction in the stable phase after surgery is compelling because these outcome measures offer distinct perspectives on assessing the kidney-protective treatment effect. As the lead investigator of the AKITA trial, I am eager to see the compound's further development progress and ultimate contribution to improving patient outcomes," said Prof.

Guard therapeutics

The global study is planned to be conducted in Europe and North America under the guidance of Prof. The randomised, double-blind, placebo-controlled global phase 2 study of ROSgard is expected to include around patients who are undergoing open heart surgery and are thus at risk of developing acute kidney injury. The study is planned to start in the first quarter of and German study centres are expected to recruit a significant proportion of the total number of patients.

Camioneta jeep 2010

All content on FT. The company has thus achieved an important milestone by expanding the clinical development program to a second indication where RMC has the potential to protect against acute kidney injuries. Speqta AB publ. All markets data located on FT. The peptide GTX, along with other similar peptides, has demonstrated robust therapeutic effects in several experimental models representing various forms of kidney disease, including kidney injuries caused by oxygen deprivation known as ischemia-reperfusion injury and by the chemotherapy agent cisplatin. Click or tap a row for details. Fable Media Group AB. Maximum Entertainment AB. Acute kidney injury is a large market. Data as of Mar 01 Any information that you receive via FT. Professor David Goldsmith, adjunct professor at King's College in London and a globally recognized Key Opinion Leader in nephrology, delivered a comprehensive presentation on irreversible loss of kidney function following open-heart surgery, highlighting the lack of specific treatment options despite the significant medical need. Institutional shareholders Top holders Movers.

Guard Therapeutics is a Swedish biotechnology company that develops novel therapies for diseases with a great medical need for more effective treatments. Our key therapeutic area is nephrology with a focus on acute kidney injuries.

Click or tap a row for details. Data as of Mar 01 The program began with the company's CEO, Tobias Agervald, providing a summary of the strategic considerations and positive feedback from the FDA that form the basis for the next development stages of RMC, including a planned Phase 2b study in open-heart surgery. HomeMaid AB publ. The Company conducts development and commercialization of treatment and diagnostics based on the alphamicroglobulin A1M protein. The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. Guard Therapeutics receives media attention after research view by Danske Bank Read more. Actions Add to watchlist Add to portfolio Add an alert. Read more. Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC ROSgard in kidney transplantation. English Swedish. Furthermore, the discussion also covered the way forward and the strategy for an upcoming pivotal Phase 3 study. A1M is a candidate for different therapeutic and diagnostic u ses, such as alleviation of autoimmune diseases and stroke treatment. Use our equities screener to discover other potential opportunities.